AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25440230 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-isolated EDs)
Number of subjects: 307
Study 22592864 — intervention group
Group type: EXPERIMENTAL
Intervention: Frovatriptan 2.5 mg
Number of subjects: 67
Study 22592864 — intervention group
Group type: COMPARATOR
Intervention: Almotriptan 12.5 mg
Number of subjects: 67
Study 20173677 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombivax HB (10 microg hepatitis B surface antigen)
Number of subjects: 123
Study 20173677 — intervention group
Group type: EXPERIMENTAL
Intervention: Twinrix (20 microg hepatitis B surface antigen and 720 EL.U hepatitis A antigen)
Number of subjects: 123
Study 18623197 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Number of subjects: 8
Study 18623197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 16182896 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 20 mg/kg dose of ciprofloxacin
Number of subjects: 180
Study 16182896 — intervention group
Group type: COMPARATOR
Intervention: 12.5 mg/kg of erythromycin every 6 h for 3 days
Number of subjects: 180
Study 12468135 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg E(2) and 0.5 mg NETA for 28 days
Number of subjects: 446
Study 12468135 — intervention group
Group type: COMPARATOR
Intervention: 0.625 mg CEE for 28 days and 5 mg MG for the final 14 days
Number of subjects: 446
Study 12468135 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg E(2) and 0.5 mg NETA
Number of subjects: 446
Study 12840859 — intervention group
Group type: EXPERIMENTAL
Intervention: Chanlibao (CLB)
Number of subjects: 161
Study 12840859 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OTC)
Number of subjects: 161
Study 12840859 — intervention group
Group type: COMPARATOR
Intervention: Control (natural labor, no drug)
Number of subjects: 161
Study 8915784 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal radius bone
Number of subjects: 18
Study 8915784 — intervention group
Group type: COMPARATOR
Intervention: Iliac crest bone
Number of subjects: 18
Study 1920461 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP)
Number of subjects: 0
Study 1920461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6763357 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg (Group A)
Number of subjects: 35
Study 6763357 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 600 mg (Group B)
Number of subjects: 35
Study 30794304 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg per day of DHA
Number of subjects: 350
Study 30794304 — intervention group
Group type: COMPARATOR
Intervention: Placebo (half soy and half corn oil)
Number of subjects: 350
Study 28130552 — intervention group
Group type: EXPERIMENTAL
Intervention: MSDK (melatonin, strontium (citrate), vitamin D3 and vitamin K2)
Number of subjects: 100
Study 28130552 — intervention group
Group type: EXPERIMENTAL
Intervention: MSDK
Number of subjects: 100
Study 25351284 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 3.75%
Number of subjects: 319
Study 24188512 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) therapy for PTSD, 10 weekly sessions
Number of subjects: 64
Study 23064072 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose FP chemotherapy (continuous 5-FU 500mg/day with intermittent CDDP 10mg/day)
Number of subjects: 1
Study 23064072 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose FP chemotherapy (same regimen resumed after recurrence)
Number of subjects: 1
Study 18634707 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of lactitol and Lactobacillus acidophilus NCFM, consumed twice daily for 2 weeks
Number of subjects: 0
Study 18634707 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sucrose)
Number of subjects: 0
Study 18634707 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of lactitol and Lactobacillus acidophilus NCFM
Number of subjects: 0
Study 17497139 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose venlafaxine
Number of subjects: 24
Study 17497139 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose sertraline
Number of subjects: 24
Study 17497139 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose citalopram
Number of subjects: 24
Study 15055667 — intervention group
Group type: EXPERIMENTAL
Intervention: Etching time of 5 seconds
Number of subjects: 39
Study 15055667 — intervention group
Group type: EXPERIMENTAL
Intervention: Etching time of 15 seconds
Number of subjects: 39
Study 15055667 — intervention group
Group type: EXPERIMENTAL
Intervention: Etching time of 30 seconds
Number of subjects: 39
Study 15055667 — intervention group
Group type: EXPERIMENTAL
Intervention: Etching time of 60 seconds
Number of subjects: 39
Study 11860668 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Care
Number of subjects: 84
Study 11860668 — intervention group
Group type: COMPARATOR
Intervention: Rational Rehabilitation
Number of subjects: 84
Study 10067020 — intervention group
Group type: EXPERIMENTAL
Intervention: Band ligation (BL)
Number of subjects: 58
Study 10067020 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy (Scl)
Number of subjects: 58
Study 9618066 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 182
Study 2205379 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal recombinant interleukin‐2 (rIL‐2) and lymphokine‐activated killer cells (LAK)
Number of subjects: 10
Study 2205379 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal rIL‐2 at 8 X 10(6) units/m2/dose
Number of subjects: 10
Study 2205379 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal rIL‐2 and LAK infusion
Number of subjects: 10
Study 2205379 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal rIL‐2 infusion
Number of subjects: 10
Study 523778 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth protein complex (Bicitropeptide)
Number of subjects: 43
Study 523778 — intervention group
Group type: COMPARATOR
Intervention: Antacid
Number of subjects: 43
Study 523778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 30653413 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 23
Study 30653413 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 23
Study 28242860 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep intervention (sleep and combination)
Number of subjects: 802
Study 28242860 — intervention group
Group type: COMPARATOR
Intervention: FAB intervention (FAB and combination)
Number of subjects: 802
Study 28242860 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 802
Study 26066705 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-hormone artificial pancreas
Number of subjects: 33
Study 26066705 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-hormone artificial pancreas
Number of subjects: 33
Study 26066705 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional insulin pump therapy
Number of subjects: 33
Study 23386157 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic appendectomy (SILA)
Number of subjects: 75
Study 23386157 — intervention group
Group type: COMPARATOR
Intervention: Open Appendectomy (OA)
Number of subjects: 75
Study 23386157 — intervention group
Group type: COMPARATOR
Intervention: Standard 3-port Laparoscopic Appendectomy (SLA)
Number of subjects: 75
Study 21131632 — intervention group
Group type: EXPERIMENTAL
Intervention: Full anonymity
Number of subjects: 150
Study 21131632 — intervention group
Group type: EXPERIMENTAL
Intervention: Quasi anonymity
Number of subjects: 150
Study 21131632 — intervention group
Group type: COMPARATOR
Intervention: Traditional confidentiality
Number of subjects: 150
Study 19158369 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermagate 1 g three times daily
Number of subjects: 63
Study 19158369 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermagate 2 g three times daily
Number of subjects: 63
Study 19158369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 17359569 — intervention group
Group type: EXPERIMENTAL
Intervention: Home health care through a combination of traditional face‐to‐face and telemedicine visits (n = 83)
Number of subjects: 161
Study 17359569 — intervention group
Group type: COMPARATOR
Intervention: Conventional home care (n = 78)
Number of subjects: 161
Study 17359569 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telecare services
Number of subjects: 161
Study 14558885 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral diet with glutamine and probiotics (n=10)
Number of subjects: 20
Study 14558885 — intervention group
Group type: COMPARATOR
Intervention: Control group (early enteral diet without glutamine and probiotics, n=10)
Number of subjects: 20
Study 14558885 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 11491008 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (10 mg/kg at 0 h, then 5 mg/kg at 6 h)
Number of subjects: 50
Study 11491008 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (4 mg/kg on day 0, then 2 mg/kg on day 1 to 4)
Number of subjects: 50
Study 11491008 — intervention group
Group type: COMPARATOR
Intervention: In vitro sensitivity tests for chloroquine
Number of subjects: 50
Study 11491008 — intervention group
Group type: COMPARATOR
Intervention: In vitro sensitivity tests for mefloquine
Number of subjects: 50
Study 11491008 — intervention group
Group type: COMPARATOR
Intervention: In vitro sensitivity tests for quinine
Number of subjects: 50
Study 11491008 — intervention group
Group type: COMPARATOR
Intervention: In vitro sensitivity tests for artemisinin
Number of subjects: 50
Study 9875997 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality sigmoidoscopy simulator training
Number of subjects: 10
Study 9875997 — intervention group
Group type: COMPARATOR
Intervention: Control group (no simulator training)
Number of subjects: 10
Study 7979523 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (40 mg/day)
Number of subjects: 33
Study 7979523 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone (2.5 mg/day)
Number of subjects: 33
Study 7979523 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 33
Study 3261651 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 268
Study 3261651 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment (ungrafted arteries)
Number of subjects: 268
Study 3261651 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (grafted arteries)
Number of subjects: 268
Study 3261651 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (closed grafts)
Number of subjects: 268
Study 3261651 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafted arteries (patent vs closed)
Number of subjects: 268
Study 3261651 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery treatment (regardless of type)
Number of subjects: 268
Study 31144431 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with dapagliflozin 5 mg/d plus saxagliptin 5 mg/d added to metformin
Number of subjects: 883
Study 31144431 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy with dapagliflozin added to metformin
Number of subjects: 883
Study 31144431 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy with saxagliptin added to metformin
Number of subjects: 883
Study 31144431 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 883
Study 31144431 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy with dapagliflozin
Number of subjects: 883
Study 31144431 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy with saxagliptin
Number of subjects: 883
Study 29110216 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional economic incentives (CEIs)
Number of subjects: 227
Study 26656981 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative treatment including moxibustion therapy conducted twice a week for 4 weeks on bilateral acupoints SP6, LR3, and CV4.
Number of subjects: 60
Study 26656981 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative treatment including moxibustion therapy.
Number of subjects: 60
Study 26656981 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (watchful waiting or oral medication including α blocker, 5α-reductase inhibitors or antimuscarinic drugs).
Number of subjects: 60
Study 22237557 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-type diet with close dietetic supervision
Number of subjects: 90
Study 21074214 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg daily
Number of subjects: 0
Study 21074214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19438082 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed learning (SDL) kit
Number of subjects: 0
Study 19438082 — intervention group
Group type: COMPARATOR
Intervention: Traditional instructor-led course
Number of subjects: 0
Study 16503717 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg/day
Number of subjects: 0
Study 16503717 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 50 mg/day
Number of subjects: 0
Study 16503717 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 200 mg/day
Number of subjects: 0
Study 16503717 — intervention group
Group type: COMPARATOR
Intervention: Topiramate
Number of subjects: 0
Study 15523351 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 57
Study 15523351 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 57
Study 11422959 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation on a weekly basis
Number of subjects: 553
Study 11422959 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthelmintic treatment at the beginning and week 12
Number of subjects: 553
Study 11422959 — intervention group
Group type: EXPERIMENTAL
Intervention: Both iron supplementation and anthelmintic treatment
Number of subjects: 553
Study 11422959 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 553
Study 11422959 — intervention group
Group type: EXPERIMENTAL
Intervention: All three worms (Ascaris lumbricoides, Trichuris trichiura, hookworms)
Number of subjects: 553
Study 11422959 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower haemoglobin values and anaemia (< 120 g/l Hb)
Number of subjects: 553
Study 11422959 — intervention group
Group type: EXPERIMENTAL
Intervention: Taller women with greater arm circumference
Number of subjects: 553
Study 9050126 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% blockade of the bromocriptine GH response
Number of subjects: 21
Study 9050126 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% blockade of the bromocriptine GH response
Number of subjects: 21
Study 9050126 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ng/ml haloperidol
Number of subjects: 21
Study 9050126 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% blockade of the GH response
Number of subjects: 21
Study 9050126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 8223165 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (6.25mg)
Number of subjects: 98
Study 8223165 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (12.5mg)
Number of subjects: 98
Study 8223165 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 98
Study 8223165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 3544626 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE) combined with low-dose heparin (LDH)
Number of subjects: 114
Study 3544626 — intervention group
Group type: COMPARATOR
Intervention: Intermittent pneumatic calf compression (IPCC)
Number of subjects: 114
Study 3544626 — intervention group
Group type: COMPARATOR
Intervention: Intermittent pneumatic calf compression (IPCC) with graduated pressure stockings
Number of subjects: 114
Study 28946789 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy treatment for borderline personality disorder over four months
Number of subjects: 8
Study 28946789 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping capacities
Number of subjects: 8
Study 28946789 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized treatments for personality disorders
Number of subjects: 8
Study 29759590 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI screening
Number of subjects: 8061
Study 26615181 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose analgesia
Number of subjects: 93
Study 26615181 — intervention group
Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 93
Study 24962666 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D supplementation (1,000 mg calcium per day and 50,000 U vitamin D3 pearl twice during the study)
Number of subjects: 56
Study 24962666 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D supplementation
Number of subjects: 56
Study 24962666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 21990519 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment with stenting
Number of subjects: 600
Study 21990519 — intervention group
Group type: COMPARATOR
Intervention: Endovascular treatment without stenting
Number of subjects: 600
Study 20113759 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential therapy with amplitude-modulated frequency (100Hz)
Number of subjects: 46
Study 20113759 — intervention group
Group type: COMPARATOR
Intervention: Interferential therapy without amplitude-modulated frequency (0Hz)
Number of subjects: 46
Study 20113759 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (with and without amplitude-modulated frequency)
Number of subjects: 46
Study 16978739 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.15 mg/kg
Number of subjects: 280
Study 16978739 — intervention group
Group type: COMPARATOR
Intervention: Morphine 0.10 mg/kg
Number of subjects: 280
Study 15957994 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapartum fentanyl (dose range 8-500 micrograms)
Number of subjects: 425
Study 15957994 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 425
Study 11912393 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (2 mM in 30 ml ethanol plus 70 ml 0.9% sodium chloride)
Number of subjects: 24
Study 11912393 — intervention group
Group type: COMPARATOR
Intervention: Resiniferatoxin (100 nM in 100 ml 0.9% sodium chloride)
Number of subjects: 24
Study 9877147 — intervention group
Group type: EXPERIMENTAL
Intervention: ATHR (heart rate threshold)
Number of subjects: 10
Study 9877147 — intervention group
Group type: EXPERIMENTAL
Intervention: AT4 (4 mmol x l(‐1) threshold)
Number of subjects: 10
Study 9877147 — intervention group
Group type: EXPERIMENTAL
Intervention: IAT (individual anaerobic threshold)
Number of subjects: 10
Study 9877147 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exercise test (PET) at ATHR power output
Number of subjects: 10
Study 8560416 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP (0.3 microgram/kg intravenous infusion)
Number of subjects: 18
Study 8560416 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP (0.3 microgram/kg intravenous infusion) in Group I patients
Number of subjects: 18
Study 8560416 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP (0.3 microgram/kg intravenous infusion) in Group II patients
Number of subjects: 18
Study 8560416 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP (0.3 microgram/kg intravenous infusion) in Group III patients
Number of subjects: 18
Study 2617655 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 47
Study 2617655 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulphamethoxazole
Number of subjects: 47
Study 2617655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 81125 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-globulin intramuscularly administered 24 hours after infection
Number of subjects: 24
Study 81125 — intervention group
Group type: COMPARATOR
Intervention: Control group (no gamma-globulin)
Number of subjects: 24
Study 31862312 — intervention group
Group type: EXPERIMENTAL
Intervention: Single supra-therapeutic inhaled dose of BDP/FF/GB pMDI (BDP/FF/GB 400/24/50 µg)
Number of subjects: 24
Study 31862312 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic inhaled dose of BDP/FF/GB pMDI (BDP/FF/GB 200/12/25 µg), twice daily for 7 consecutive days
Number of subjects: 24
Study 31862312 — intervention group
Group type: COMPARATOR
Intervention: Both groups (therapeutic and supra-therapeutic)
Number of subjects: 24
Study 30690191 — intervention group
Group type: COMPARATOR
Intervention: Exercise with oral placebo (Group A)
Number of subjects: 66
Study 30690191 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise with oral metformin (Group B)
Number of subjects: 66
Study 26644202 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK therapy
Number of subjects: 117
Study 26116294 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-guided in-bore biopsy (IB-GB)
Number of subjects: 267
Study 26116294 — intervention group
Group type: COMPARATOR
Intervention: MRI-ultrasound fusion-guided biopsy (FUS-GB) + transrectal ultrasound-guided biopsy (TRUS-GB)
Number of subjects: 267
Study 23459854 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised resistance training program (8 exercises, 2 sets, 10-15 repetitions, 3 times/week)
Number of subjects: 29
Study 23459854 — intervention group
Group type: COMPARATOR
Intervention: Supervised stretching program (25-30 min/session, 2 times/week)
Number of subjects: 29
Study 21303634 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous bolus insulin injections once an hour
Number of subjects: 10
Study 21303634 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion
Number of subjects: 10
Study 21303634 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous insulin infusion
Number of subjects: 10
Study 19394034 — intervention group
Group type: EXPERIMENTAL
Intervention: Insurance intervention
Number of subjects: 4070
Study 19394034 — intervention group
Group type: COMPARATOR
Intervention: Delay in care
Number of subjects: 4070